Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

EnteroMedics Inc. ($ETRM) stock showed strong moves in its Tuesday trading session as it jumped to its intraday high of $30.41. The stock eventually closed at $27.70, up 56.5% from its previous close. The company recently announced the development of its new treatment called vBloc. The treatment is designed to be a weight loss therapy.
The company’s prospects are further strengthened by its another news of securing two new facilities for implanting its technology. These two facilities are Roper St. Francis in South Carolina and MedStar Health in Maryland. The company stock has surged over 1200% this year so far. At the very same time, it is still way lower than its 52 weeks high of $132.30, thus offering considerable upside.

Roche ($RHHBY) announced acquiring privately-held Menlo Park, CA-based ForSight VISION4, a venture capital-backed biotech developing eye drugs delivered via an intravitreal implant called PDS. Both the companies have been collaborating since 2010 for developing long-acting delivery of therapeutics to the eye.
The deal stipulates the payment of upfront amount by Roche, which will also make earn-out payments related to the achievement of development and commercial milestones. Specific financial terms of the deal have not been disclosed by the concerned parties. Roche ($RHHBY) stock has lost nearly 8% of its value in the past one year. However, it gained over 7% in the past one month, showing the signs of recovery.


• Takeda Pharmaceuticals ($TKPYY) announced acquisition of Ariad Pharmaceuticals for $5.2 billion. The company said it is willing to acquire more companies in the future.
• Valeant ($VRX) announced selling its three skincare brands including Ambi, AcneFree and CeraVe to L’Oreal ($LRLCY) in a $1.3 billion deal.

• Neuralstem ($CUR) has been granted the US patent No. 9,540,611 covering methods for treating and/reversing neurodegenerative diseases via the use of neural stem cells obtained from spinal cord tissue.
• Dr. Reddy’s Laboratories ($RDY) reported its plan to launch two products in the US. These products are Nystatin and Triamcinolone Acetonide Cream USP, the generic equivalent of Taro Pharmaceuticals' product and Raloxifene hydrochloride tablets, the generic equivalent of Eli Lilly's Evista.

• Natera ($NTRA) announced terminating its distribution agreement with Bioreference Laboratories. The company will now directly promote its prenatal screening test Panorama.
• LabCorp ($LH) reported striking a deal with Mount Sinai Health system for acquiring its Clinical Outreach Laboratories. The companies did not disclose the financial details.

• Orthofix International ($OFIX) announced its preliminary fourth quarter sales at $109 million. The company forecast its 2017 revenue in the range of $407 million and $411 million.
• Pyng Medical ($PYNGF) reported its fourth quarter net loss at $0.07 million. The company’s revenue for the quarter stood at $1.51 million.

• Regeneron ($REGN) reported receiving Hold rating from Chardan Capital. The price target for the stock has been set at $345.
• Puma Biotechnology ($PBYI) received Buy rating from JPMorgan.

Gainers (% price change) Last Trade Change Mkt Cap
EnteroMedics Inc
27.70 +10.00 (56.50%) 127.46M
Sarepta Therapeutics Inc
37.89 +6.63 (21.21%) 2.15B
Illumina, Inc.
165.04 +23.50 (16.60%) 24.25B
Brookdale Senior Living
14.80 +1.95 (15.18%) 2.79B
Accelerate Diagnostics
23.20 +2.85 (14.00%) 1.21B
Losers (% price change)
Abaxis Inc
48.59 -6.43 (-11.69%) 1.12B
Neurocrine Biosciences
42.61 -2.39 (-5.31%) 3.78B
Impax Laboratories Inc
12.70 -0.70 (-5.22%) 910.99M
Zeltiq Aesthetics Inc
40.71 -2.00 (-4.68%) 1.61B
CTI BioPharma Corp
5.52 -0.26 (-4.50%) 187.64M
Most Actives (dollar volume)
Ariad Pharmaceuticals
23.68 -0.07 (-0.29%) 7.95B
Illumina, Inc.
165.04 +23.50 (16.60%) 24.25B
Merck & Co., Inc.
59.92 -1.18 (-1.93%) 167.48B
90.83 +0.04 (0.04%) 9.45B
Valeant Pharmaceuticals
16.40 +1.05 (6.84%) 5.62B